vs
Side-by-side financial comparison of Entrada Therapeutics, Inc. (TRDA) and Voyager Technologies, Inc. (VOYG). Click either name above to swap in a different company.
Voyager Technologies, Inc. is the larger business by last-quarter revenue ($35.2M vs $20.6M, roughly 1.7× Entrada Therapeutics, Inc.). Entrada Therapeutics, Inc. runs the higher net margin — -84.4% vs -130.4%, a 46.0% gap on every dollar of revenue. On growth, Voyager Technologies, Inc. posted the faster year-over-year revenue change (2.1% vs -65.2%). Entrada Therapeutics, Inc. produced more free cash flow last quarter ($-39.7M vs $-66.8M).
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
TRDA vs VOYG — Head-to-Head
Income Statement — Q1 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.6M | $35.2M |
| Net Profit | $-17.3M | $-45.9M |
| Gross Margin | — | -4.4% |
| Operating Margin | -106.0% | — |
| Net Margin | -84.4% | -130.4% |
| Revenue YoY | -65.2% | 2.1% |
| Net Profit YoY | -173.8% | -64.5% |
| EPS (diluted) | $-0.42 | $-0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $35.2M | ||
| Q4 25 | — | $46.7M | ||
| Q3 25 | — | $39.6M | ||
| Q2 25 | — | $45.7M | ||
| Q1 25 | $20.6M | — | ||
| Q4 24 | $37.4M | — | ||
| Q3 24 | $19.6M | — | ||
| Q2 24 | $94.7M | — |
| Q1 26 | — | $-45.9M | ||
| Q4 25 | — | $-33.0M | ||
| Q3 25 | — | $-16.3M | ||
| Q2 25 | — | $-31.4M | ||
| Q1 25 | $-17.3M | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | $55.0M | — |
| Q1 26 | — | -4.4% | ||
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 15.4% | ||
| Q2 25 | — | 18.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -60.7% | ||
| Q2 25 | — | -52.8% | ||
| Q1 25 | -106.0% | — | ||
| Q4 24 | -15.7% | — | ||
| Q3 24 | -110.7% | — | ||
| Q2 24 | 56.4% | — |
| Q1 26 | — | -130.4% | ||
| Q4 25 | — | -70.7% | ||
| Q3 25 | — | -41.1% | ||
| Q2 25 | — | -68.7% | ||
| Q1 25 | -84.4% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | -71.7% | — | ||
| Q2 24 | 58.1% | — |
| Q1 26 | — | $-0.75 | ||
| Q4 25 | — | $-0.52 | ||
| Q3 25 | — | $-0.28 | ||
| Q2 25 | — | $-1.23 | ||
| Q1 25 | $-0.42 | — | ||
| Q4 24 | $-0.20 | — | ||
| Q3 24 | $-0.35 | — | ||
| Q2 24 | $1.55 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $67.8M | $429.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $417.3M | $404.5M |
| Total Assets | $486.5M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $429.4M | ||
| Q4 25 | — | $491.3M | ||
| Q3 25 | — | $413.3M | ||
| Q2 25 | — | $468.9M | ||
| Q1 25 | $67.8M | — | ||
| Q4 24 | $101.2M | — | ||
| Q3 24 | $78.0M | — | ||
| Q2 24 | $185.3M | — |
| Q1 26 | — | $404.5M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $590.9M | ||
| Q2 25 | — | $554.7M | ||
| Q1 25 | $417.3M | — | ||
| Q4 24 | $428.7M | — | ||
| Q3 24 | $422.4M | — | ||
| Q2 24 | $429.9M | — |
| Q1 26 | — | $1.0B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $727.8M | ||
| Q2 25 | — | $685.3M | ||
| Q1 25 | $486.5M | — | ||
| Q4 24 | $526.3M | — | ||
| Q3 24 | $554.6M | — | ||
| Q2 24 | $582.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.5M | $-39.7M |
| Free Cash FlowOCF − Capex | $-39.7M | $-66.8M |
| FCF MarginFCF / Revenue | -192.9% | -189.5% |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-58.0M | $-263.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-39.7M | ||
| Q4 25 | — | $-60.9M | ||
| Q3 25 | — | $-15.1M | ||
| Q2 25 | — | $-30.9M | ||
| Q1 25 | $-38.5M | — | ||
| Q4 24 | $-31.6M | — | ||
| Q3 24 | $-24.3M | — | ||
| Q2 24 | $39.8M | — |
| Q1 26 | — | $-66.8M | ||
| Q4 25 | — | $-54.5M | ||
| Q3 25 | — | $-53.8M | ||
| Q2 25 | — | $-88.8M | ||
| Q1 25 | $-39.7M | — | ||
| Q4 24 | $-32.2M | — | ||
| Q3 24 | $-24.9M | — | ||
| Q2 24 | $38.8M | — |
| Q1 26 | — | -189.5% | ||
| Q4 25 | — | -116.9% | ||
| Q3 25 | — | -135.8% | ||
| Q2 25 | — | -194.4% | ||
| Q1 25 | -192.9% | — | ||
| Q4 24 | -86.2% | — | ||
| Q3 24 | -127.3% | — | ||
| Q2 24 | 41.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 97.8% | ||
| Q2 25 | — | 126.7% | ||
| Q1 25 | 5.6% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 3.3% | — | ||
| Q2 24 | 1.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -27.94× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
